Isolation and immunological characterization of a group of new B lymphomas from CBA mice

Venkatachalam Udhayakumar, Peter H. Brodeur, M. S. Rajagopalan, Stephen Zimmer, Karen Pollok, Bondada Subbarao

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We have isolated and characterized a new series of B lymphomas which occurred spontaneously in a group of CBA N mice that were transferred with spleen or lymph node cells from 24-month-old CBA Ca mice. Tumor cell lines from six CBA N mice that received spleen cells were rescued and designated as BKS-2, BKS-3, BKS-4, BKS-5, BKS-6, and BKS-7. Also, tumor cells from a recipient of lymph node cells were rescued and the resulting cell line was designated BKL. These tumor cells expressed membrane immunoglobulin (μ,κ), major histocompatibility complex Class I and Class II molecules, B220, Lyb8, Fc receptors, J11d, interleukin 2 receptors, and Ly1. All of the tumors did not express the T cell specific markers Thy 1.2, L3T4, and Lyt2.1. They appeared to be clonal in origin, since they exhibited common rearrangements at both heavy and light chain immunoglobulin loci. Phenotypically, these lymphomas appeared to be analogous to immature B cells. Also, these lymphomas displayed different functional reactivities when treated with various B cell mitogens and growth factors in vitro. Anti-μ antibodies which normally induce B cell growth inhibited the proliferation of these lymphoma cells in vitro, whereas they responded to lipopolysaccharide, T cell-derived growth factors, and interleukin 5 by enhanced proliferation. These tumor cells expressed constitutively high levels of c-myc mRNA.

Original languageEnglish (US)
Pages (from-to)240-251
Number of pages12
JournalClinical Immunology and Immunopathology
Volume51
Issue number2
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Inbred CBA Mouse
Lymphoma
Neoplasms
B-Lymphocytes
Spleen
Lymph Nodes
Immunoglobulin Light Chains
Immunoglobulin Heavy Chains
B-Lymphoid Precursor Cells
Fc Receptors
Interleukin-2 Receptors
Interleukin-5
Tumor Cell Line
Major Histocompatibility Complex
Mitogens
Interleukin-2
Lipopolysaccharides
Immunoglobulins
Anti-Idiotypic Antibodies
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Isolation and immunological characterization of a group of new B lymphomas from CBA mice. / Udhayakumar, Venkatachalam; Brodeur, Peter H.; Rajagopalan, M. S.; Zimmer, Stephen; Pollok, Karen; Subbarao, Bondada.

In: Clinical Immunology and Immunopathology, Vol. 51, No. 2, 1989, p. 240-251.

Research output: Contribution to journalArticle

Udhayakumar, Venkatachalam ; Brodeur, Peter H. ; Rajagopalan, M. S. ; Zimmer, Stephen ; Pollok, Karen ; Subbarao, Bondada. / Isolation and immunological characterization of a group of new B lymphomas from CBA mice. In: Clinical Immunology and Immunopathology. 1989 ; Vol. 51, No. 2. pp. 240-251.
@article{7c45ab3c493a4fffaa58807eba90891a,
title = "Isolation and immunological characterization of a group of new B lymphomas from CBA mice",
abstract = "We have isolated and characterized a new series of B lymphomas which occurred spontaneously in a group of CBA N mice that were transferred with spleen or lymph node cells from 24-month-old CBA Ca mice. Tumor cell lines from six CBA N mice that received spleen cells were rescued and designated as BKS-2, BKS-3, BKS-4, BKS-5, BKS-6, and BKS-7. Also, tumor cells from a recipient of lymph node cells were rescued and the resulting cell line was designated BKL. These tumor cells expressed membrane immunoglobulin (μ,κ), major histocompatibility complex Class I and Class II molecules, B220, Lyb8, Fc receptors, J11d, interleukin 2 receptors, and Ly1. All of the tumors did not express the T cell specific markers Thy 1.2, L3T4, and Lyt2.1. They appeared to be clonal in origin, since they exhibited common rearrangements at both heavy and light chain immunoglobulin loci. Phenotypically, these lymphomas appeared to be analogous to immature B cells. Also, these lymphomas displayed different functional reactivities when treated with various B cell mitogens and growth factors in vitro. Anti-μ antibodies which normally induce B cell growth inhibited the proliferation of these lymphoma cells in vitro, whereas they responded to lipopolysaccharide, T cell-derived growth factors, and interleukin 5 by enhanced proliferation. These tumor cells expressed constitutively high levels of c-myc mRNA.",
author = "Venkatachalam Udhayakumar and Brodeur, {Peter H.} and Rajagopalan, {M. S.} and Stephen Zimmer and Karen Pollok and Bondada Subbarao",
year = "1989",
doi = "10.1016/0090-1229(89)90023-8",
language = "English (US)",
volume = "51",
pages = "240--251",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Isolation and immunological characterization of a group of new B lymphomas from CBA mice

AU - Udhayakumar, Venkatachalam

AU - Brodeur, Peter H.

AU - Rajagopalan, M. S.

AU - Zimmer, Stephen

AU - Pollok, Karen

AU - Subbarao, Bondada

PY - 1989

Y1 - 1989

N2 - We have isolated and characterized a new series of B lymphomas which occurred spontaneously in a group of CBA N mice that were transferred with spleen or lymph node cells from 24-month-old CBA Ca mice. Tumor cell lines from six CBA N mice that received spleen cells were rescued and designated as BKS-2, BKS-3, BKS-4, BKS-5, BKS-6, and BKS-7. Also, tumor cells from a recipient of lymph node cells were rescued and the resulting cell line was designated BKL. These tumor cells expressed membrane immunoglobulin (μ,κ), major histocompatibility complex Class I and Class II molecules, B220, Lyb8, Fc receptors, J11d, interleukin 2 receptors, and Ly1. All of the tumors did not express the T cell specific markers Thy 1.2, L3T4, and Lyt2.1. They appeared to be clonal in origin, since they exhibited common rearrangements at both heavy and light chain immunoglobulin loci. Phenotypically, these lymphomas appeared to be analogous to immature B cells. Also, these lymphomas displayed different functional reactivities when treated with various B cell mitogens and growth factors in vitro. Anti-μ antibodies which normally induce B cell growth inhibited the proliferation of these lymphoma cells in vitro, whereas they responded to lipopolysaccharide, T cell-derived growth factors, and interleukin 5 by enhanced proliferation. These tumor cells expressed constitutively high levels of c-myc mRNA.

AB - We have isolated and characterized a new series of B lymphomas which occurred spontaneously in a group of CBA N mice that were transferred with spleen or lymph node cells from 24-month-old CBA Ca mice. Tumor cell lines from six CBA N mice that received spleen cells were rescued and designated as BKS-2, BKS-3, BKS-4, BKS-5, BKS-6, and BKS-7. Also, tumor cells from a recipient of lymph node cells were rescued and the resulting cell line was designated BKL. These tumor cells expressed membrane immunoglobulin (μ,κ), major histocompatibility complex Class I and Class II molecules, B220, Lyb8, Fc receptors, J11d, interleukin 2 receptors, and Ly1. All of the tumors did not express the T cell specific markers Thy 1.2, L3T4, and Lyt2.1. They appeared to be clonal in origin, since they exhibited common rearrangements at both heavy and light chain immunoglobulin loci. Phenotypically, these lymphomas appeared to be analogous to immature B cells. Also, these lymphomas displayed different functional reactivities when treated with various B cell mitogens and growth factors in vitro. Anti-μ antibodies which normally induce B cell growth inhibited the proliferation of these lymphoma cells in vitro, whereas they responded to lipopolysaccharide, T cell-derived growth factors, and interleukin 5 by enhanced proliferation. These tumor cells expressed constitutively high levels of c-myc mRNA.

UR - http://www.scopus.com/inward/record.url?scp=0024507953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024507953&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(89)90023-8

DO - 10.1016/0090-1229(89)90023-8

M3 - Article

C2 - 2649295

AN - SCOPUS:0024507953

VL - 51

SP - 240

EP - 251

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -